Key pathological features of Parkinson's Disease (PD) include the progressive degeneration of midbrain dopaminergic (DA) neurons and hindbrain noradrenergic (NA) neurons. The loss of DA neurons has been extensively studied and is the main cause of motor dysfunction. Importantly, however, there are a range of 'non-movement' related features of PD including cognitive dysfunction, sleep disturbances and mood disorders. The origins for these non-motor symptoms are less clear, but a possible substrate for cognitive decline may be reduced adult-hippocampal neurogenesis, which is reported to be impaired in PD. The mechanisms underlying reduced neurogenesis in PD are not well established. Here we tested the hypothesis that NA and DA depletion, as occurs in PD, impairs hippocampal neurogenesis. We used 6-hydroxydopamine or the immunotoxin dopamine-b-hydroxylase-saporin to selectively lesion DA or NA neurons, respectively, in adult Sprague Dawley rats and assessed hippocampal neurogenesis through phenotyping of cells birthdated using 5-bromo-2 0 -deoxyuridine. The results showed no difference in proliferation or differentiation of newborn cells in the subgranular zone of the dentate gyrus after NA or DA lesions.
| I N TR ODU C TI ON
Parkinson's disease (PD) is a neurodegenerative disease that mostly affects individuals over 60 years old. The pathology of PD is generally described as a degeneration of dopamine (DA) neurons of the substantia nigra pars compacta (SNpc), which leads to motor impairments that include rigidity, tremor, and bradykinesia (Samii, Nutt, & Ransom, 2004) . However, PD is a multisystem disorder, and the progressive pathology also impacts various other nuclei including the locus coeruleus (LC; Halliday, 2012; Zweig, Cardillo, Cohen, Giere, & Hedreen, 1993) , basal forebrain (Hall et al., 2014; Nakano & Hirano, 1984) , olfactory structures (Pearce, Hawkes, & Daniel 1995) and the raphe nuclei (Halliday, Blumbergs, Cotton, Blessing, & Geffen, 1990 ).
While often described as a motor disease, PD patients also exhibit a wide range of non-motor symptoms, including olfactory impairment, depression, and mild cognitive impairments progressing to dementia in late-stage disease (Barbosa, 2013) . Thus, exploring the relationship between nonmotor symptoms and patterns of pathology in specific brain regions is becoming an increasingly important area in PD Hippocampal neurogenesis has been linked to cognitive function and is reportedly reduced in parallel with the onset of age-related cognitive decline (Small, Schobel, Buxton, Witter, & Barnes, 2012) . Furthermore, hippocampal neurogenesis has been suggested to be deficient in PD patients, with MRI studies showing that PD patients with dementia have smaller hippocampi than patients without dementia (Camicioli et al., 2003; Laakso et al., 1996) . H€ oglinger et al. (2004) also investigated hippocampal neurogenesis levels in PD patients, reporting fewer numbers of neuronal precursors.
Since the reports correlating impaired hippocampal neurogenesis to nonmotor symptoms in PD patients, a number of studies have focused on identifying factors responsible for regulating hippocampal neurogenesis in order to identify therapeutic targets (Geraerts, Krylyshkina, Debyser, & Baekelandt, 2007; Kotani, Yamauchi, Teramoto, & Ogura, 2008; Malberg, Eisch, Nestler, & Duman, 2000; Meneghini et al., 2014; Vaidya, Vadodaria, & Jha, 2007) . DA degeneration has been suggested to be a key factor underlying a decrease in neurogenesis in the hippocampus (H€ oglinger et al., 2004; Park & Enikolopov, 2010; Suzuki et al., 2010) . Indeed, Suzuki et al. (2010) used 6-hydroxydopamine (6-OHDA) to remove midbrain DA neurons and observed a reduction of proliferating cells in the subgranular zone (SGZ) of the dentate gyrus (DG), a finding also reported in a study using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (H€ oglinger et al., 2004) . However, the specificity of both 6-OHDA and MPTP are not limited to DA. 6-OHDA targets all catecholamines (Breese & Traylor, 1970) and MPTP also affects noradrenaline (NA) and serotonin (5HT) neurons (Gupta, Felten, & Gash, 1984; Namura et al., 1987) . Consequently, it is possible that NA depletion was underestimated in these previous studies, and may play an important role in the reduced hippocampal neurogenesis reported.
Supporting this hypothesis, we recently demonstrated that the DG, which receives a dense innervation from NA neurons originating in the LC, completely lacks innervation from midbrain DA neurons (Ermine, Wright, Parish, Stanic, & Thompson, 2016) . Furthermore, reports that NA neuronal degeneration may precede DA neuronal degeneration in PD (Braak & Del Tredici, 2008) , combined with nonmotor symptoms that arise prior to motor dysfunction (Tolosa, Compta, & Gaig 2007) , provides correlative support for the hypothesis that NA plays a role in regulating cell proliferation and neurogenesis in the SGZ. To test this, we compared the effect of DA depletion and NA depletion alone, or together, on cell proliferation and neurogenesis in the SGZ of adult rats. 
| Surgical procedures
The rats were anesthetised with isoflurane (5% at 1 L/min) and maintained under anaesthesia for the duration of the surgery (2%, 1 L/min).
The animals were placed in a stereotaxic frame (Kopf, Germany) and a small burr-hole was drilled in the skull to administer the following toxins at a rate of 1 mL/min: (1) 14 mg of 6-OHDA [Tocris, in 0.02% ascorbic acid (Sigma) and saline (0.9% NaCl)] into the medial forebrain bundle (MFB) (4.2 mm anterior and 1.2 mm lateral to bregma, 7.8 mm below dura) with i.p. injection of desipramine (20 mg/kg) 30 min prior to surgery to protect NA neurons; (2) 1 mg of dopamine-b-hydroxylase saporin (DBH-saporin) in the intra cerebral ventricle (i.c.v.; 0.6 mm anterior and 1.5 mm lateral to bregma, 3 mm below dura); (3) both 6-OHDA (14 mg in MFB) and DBH-saporin (1 mg in i.c.v.); (4) saline in MFB and/or i.c.v.
Animals were sacrificed at either four or nine weeks postlesion to confirm selective neuronal (DA and/or NA) ablation and assess the impact of the treatments on SGZ cell proliferation. The four-week time-point was chosen for its relevance to study designs in the existing literature (Baker, Baker, & Hagg, 2004; H€ oglinger et al., 2004; Suzuki et al., 2010) . The nine-week time-point allowed a sufficient time for the newborn cells to differentiate into their neuronal phenotype and investigates a longer-term effect of the lesions on neurogenesis.
2.3 | Lesion validation by assessing DA and NA levels using HPLC To validate the DA and NA lesions, we assessed DA and NA levels in the brain four weeks after lesioning using high performance liquid chromatography (HPLC). DA and NA levels were assessed at the level of terminal fields in the striatum or hippocampus, as described previously in detail (Parish et al., 2001) . In brief, animals were decapitated and the striatum and hippocampi were rapidly dissected, weighed, and snap-frozen for storage at 280 8C until analysis, at which point samples were homogenised in an extraction buffer containing 0.4M perchloric acid, 7.9 mM sodium metabisulphite, 1.34 mM disodium ethylenediaminetetra-acetic acid (EDTA) in distilled water. To rupture vesicular membranes, samples were sonicated for 15 s and centrifuged at 10,000g (3 3 5 min). The resultant supernatant was transferred to HPLC vials and placed in an autosampler for injection onto the HPLC. 
| Tissue collection and immunohistochemistry
Animals were sacrificed by a terminal dose of pentobarbitone (100 mg/kg; Virbac, Peakhurst, Australia) and transcardially perfused with paraformaldehyde media (PFA, 4% in 0.4M phosphate buffer with 0.2% picric acid).
Brains were collected and further postfixed for 2 hr in PFA, followed by cryo-protection in 20% sucrose PBS solution for 1-2 days. After freezing the brains on dry ice, 40 mm-thick coronal sections were collected in 1:12-series using a freezing-microtome (Leica, Wetzlar, Germany).
Free-floating immunohistochemistry for tyrosine hydroxylase (TH), DBH, BrdU, Ki67, and Prox1 were performed on a 1:12 or 1:6 series as previously described (Thompson, 2005) . 
| Analysis
Fluorescent microscopic analysis and images were performed using a Zeiss Meta confocal microscope (LSM 780) and chromogenic images were captured using a Leica DM6000 microscope.
The number of BrdU1 and Ki671 cells in the SGZ were quantified across six sections located at 2.6, 2.84, 3.08, 3.32, 3.56, and 3.8 mm caudal to bregma. The number of BrdU/Prox1 double positive cells was also quantified, by random selection of 80 BrdU1 cells located in the SGZ across three to six sections (ranging from 2.6 to 3.8 mm caudal to bregma) and analysis of double-labelling through orthogonal reconstruction using the confocal microscope, to identify them as Prox1 positive or negative.
Statistical analysis was performed using a Kruskal-Wallis with Dunn's multiple comparison test to assess the difference of DA and NA levels at their terminal fields between the lesioned and saline con- | 329
FIG URE 1 DBH-saporin and 6-OHDA successfully lesion the NA and DA systems, respectively, in adult SD rats. Lesioned animals were killed at 4 weeks for confirmation of selective lesioning, or killed at 9 weeks (after 7 days of bi-daily BrdU injections at 4 weeks), to assess hippocampal neurogenesis (a). As confirmed by HPLC 4 weeks after toxin administration, NA lesions induced a 13-fold reduction in NA levels in the hippocampus (b) and DA lesions induced a 9-fold reduction of DA levels in the striatum (c), compared with their respective control groups. Immunohistochemical detection of DBH using a brightfield microscope in controls (d) and lesioned animals (e), reveals a reduction in the number of NA cell bodies in the LC 9 weeks after DBH-saporin administration. Darkfield imaging of chromogenically labelled DBH in the hippocampus shows the intact NA system in control animals (f), compared with an almost complete ablation of NA fibres in lesioned animals (g). The analysis of TH immunoreactivity 9 weeks after 6-OHDA administration showed an almost complete ablation of DA cell bodies in the right SNpc (h vs. i) and axon terminals in the striatum (j vs. To assess the effect of NA or DA loss on the differentiation of new-born cells in each group, the proportion of BrdU1 cells that adopted a Prox11 phenotype (broadly expressed in granular neurons of the SGZ) was quantified. Four weeks after BrdU administration, the percentage of BrdU1 cells to adopt a Prox11 identity in the SGZ was not significantly different from control numbers in any of the treatment groups (control: mean 6 SEM 5 76.34% 6 1.92, n 5 15; NA lesion: mean 6 SEM 5 79.53% 6 1.89, n 5 8; DA lesion: mean 6 SEM 5 75.54% 6 2.82, n 5 7; double lesion: mean 6 SEM 5 78.57% 6 2.43, n 5 7; p 5 .6016; Figure 3a -e). While a recent study found fewer proliferating cells in the SGZ after midbrain DA neuron lesions in adult rats (Suzuki et al., 2010) , reduced proliferation in the SVZ has been more widely reported following DA deficiency (Baker et al., 2004; H€ oglinger et al., 2004; Winner et al., 2006) . We aimed to confirm these reports of reduced SVZ proliferation in our experimental setting, to obtain an 'internal control' from which to contextualize the negative findings from our analysis of the hippocampus. We therefore quantified the number of BrdU1 and Ki671 cells in the SVZ across three coronal sections from animals nine weeks after lesioning (four weeks after the one-week BrdU pulse period) and compared the DA lesion and control groups. Given the almost complete absence of NA innervation of the striatum and SVZ, the NA lesion group was not assessed.
In contrast to previous reports, we found that depletion of striatal 
| D ISC USSION
These results of DA and/or NA denervation having no effect on cell proliferation and neurogenesis suggest that hippocampal neurogenesis is not directly regulated by the DA or NA systems in the adult rat brain, and thus is unlikely to directly underlie a link between loss of these neurons and cognitive decline in PD. This is consistent at a neuroanatomical level with our recent report on the lack of direct innervation of the hippocampus from midbrain DA neurons (Ermine et al., 2016) . At a functional level however, the results contrast to previous studies, where DA has been described as a regulator of adult hippocampal neurogenesis (Broussard, 2012; H€ oglinger et al., 2004; Mu, Zhao, & Gage, 2011; Suzuki et al., 2010; Wisman, Sahin, Maingay, Leanza, & Kirik, 2008) .
The existing literature is notably mixed with respect to conclusions that DA either positively or negatively regulates hippocampal neurogenesis. For example, in MPTP-induced rodent models of PD, low doses of MPTP reportedly decrease proliferation (H€ oglinger et al., 2004 ) while higher doses increase proliferation (Park & Enikolopov, 2010) . Further confusion comes from pharmacological replacement studies, where the D2 antagonist haloperidol has been reported as having no effect (Malberg et al., 2000) , decreasing (Wakade, Mahadik, Waller, & Chiu, 2002) or increasing ) SGZ proliferation levels. Haloperidol has also been reported to have no effect on (Halim, Weickert, McClintock, Weinberger, & Lipska, 2004) , and to increase (Keilhoff, Grecksch, Bernstein, Roskoden, & Becker, 2010) 
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Lindsey , & Moore, 1980) ; and particularly within the SGZ (Ermine et al., 2016) where the entirety of TH1 fibres coexpress the NA-specific marker DBH but not the DA-specific transporter (DAT). In light of this,
we hypothesised that in a recent study reporting reduced hippocampal neurogenesis in response to 6-OHDA lesion of midbrain DA neurons, "off-target" depletion of the nearby locus coeruleus NA neurons may be the relevant underlying mechanism. Surprisingly, however, we report here that hippocampal neurogenesis was insensitive to near complete depletion of the DA or NA projection systems, alone or in combination, under similar experimental conditions. Perhaps more surprising was the finding that depletion of DA innervation of the striatum and adjacent SVZ did not impair SVZ cell proliferation either. This is again in contrast to a number of studies with similar designs that report reductions in SVZ cell proliferation in response to loss of DA innervation (Baker et al., 2004; H€ oglinger et al., 2004; O'Keeffe, 2009; Sui, Horne, & Stanić, 2012) . We noted that in some of these studies, cell-proliferation was assessed at shorter intervals after DA lesioning than the nine-week time-point we originally examined. Thus, to account for the possibility we had missed a transient impact on cell-proliferation we established an additional cohort of animals for histological assessment four weeks after lesioning to match previous study designs. Nonetheless, the results were similar to those observed at nine weeks, with no difference in the number of proliferating Ki671 cells in both SGZ and SVZ despite near complete lesioning of the DA or NA projection systems.
Comparison of other key parameters in the present experimental design, including method of DA ablation, rodent species or strains, age, and sex does not really identify variables that clearly account for the descrapancy in outcome with similarly designed studies in rodents. The study by H€ oglinger et al (2004) , additionally reports reduced cell proliferation in SGZ and SVZ in patients with PD, relative to aged-matched controls, and it is possible that DA differentially regulates cell proliferation across species. This is supported by findings from Baker, Baker, and Hagg (2005) showing that activation of the D3 receptor increases BrdU labelling of SVZ progenitors in rats but not mice.
Nonetheless, while there are a number of now well-cited studies that conclude DA positively regulates SVZ cell proliferation, a detailed review of the literature highlights a lack of consensus in much the same way as has been reported for the SGZ. DA has variously been reported to increase (Baker et al., 2004; H€ oglinger et al., 2004; Van Kampen, Hagg, Robertson, & Van Kampen, 2004; Lao, Lu, & Chen, 2013; O'Keeffe, 2009; Sui et al., 2012; Winner et al., 2006 Winner et al., , 2009 , decrease (Aponso, Faull, & Connor, 2008; Liu et al., 2006) and have no impact (Baker et al., 2005; van den Berge et al., 2011; Milosevic et al., 2007) on SVZ cell proliferation (Table 1) .
In this study, we were interested in basal neurogenesis to understand the origin of the hippocampal neurogenesis decline observed in PD brains (Camicioli et al., 2003; Laakso et al., 1996) . However, hippocampal neurogenesis has been shown to be increased in an enriched environment (Kempermann, Kuhn, & Gage, 1997) or following exercise (van Praag, Shubert, Zhao, & Gage, 2005) , and it cannot be excluded that NA and/or DA can facilitate changes in the activity dependent regulation of hippocampal neurogenesis.
Identification of pathophysiological mechanisms underlying nonmotor symptoms in PD, including dementia, remains an important strategy for the development of new therapeutic approaches. Here we Studies in green have reported a positive effect of DA on proliferation, studies in red have reported a negative effect and studies in white/grey have reported no effect of DA on SVZ proliferation.
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| 335 sought to functionally link DA or NA depletion to reduced hippocampal neurogenesis as a potential substrate for cognitive decline in PD. The results do not support such a link and contribute to an already highly mixed literature regarding the role of DA for regulation of cell-turnover in the two neurogenic niches in the adult mammalian brain. Dementia linked to neurodegeneration in PD is more likely to be directly related to loss of DA and/or NA signalling in various target structures, while reduced neurogenesis and hippocampal atrophy (Camicioli et al., 2003; H€ oglinger et al., 2004; Laakso et al., 1996) 
